Partnership will include cGMP manufacturing services for AFTX-201, Affinia’s investigational gene therapy medicine for BAG3 dilated cardiomyopathy WALTHAM, Mass. and COLUMBUS, Ohio, Nov. 13, 2024 /PRNewswire/ — Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.